FOR IMMEDIATE RELEASE
May 30, 2018
LAWRENCE, KS – CritiTech Particle Engineering Solutions, a growing Contract Development Manufacturing Organization (CDMO) and expert in particle engineering, announced today the launch of its new pharmaceutical spray drying business. The company provides spray drying services to enhance the bioavailability of poorly soluble drugs (BSC II and IV), and to design and manufacture a variety of API’s and excipients.
CritiTech Particle Engineering Solutions offers spray drying services from proof-of-concept to cGMP production for a wide array of compounds, including non-potent compounds to those with an OEL down to 0.03mg/m3 (Safebridge Category 3 compounds), using organic solvents or water. It can spray dry material from milligrams to hundreds of kilograms. The company is licensed to handle substances classified by the U.S. Drug Enforcement Administration as Schedule II-V.
In addition to its spray drying services, CritiTech Particle Engineering Solutions also provides extensive on-site particle characterization and analytical services. All services are supported by an in-house quality assurance and quality control team.
The investment made in the spray drying business builds on the company’s capabilities to engineer drug particles with its proprietary Supercritical Precipitation Technology, which is used to improve the bioavailability, efficacy, pharmacokinetics, dosing, delivery and toxicity of poorly soluble drugs. CritiTech Particle Engineering Solutions has worked with over 80 drugs using its Supercritical Precipitation Technology and developed four drug products that are currently being tested in six Phase II Trials.
“CT PES is committed to providing a best-in-class CDMO experience to each and every one of its customers. Our goal is to create personal, productive, long-term, business relationships that create significant value for our clients,” said Matthew McClorey, President. “Combining spray drying with our Supercritical Precipitation Technology strengthens our particle engineering capabilities and enables us to better serve our customers’ particle engineering needs.”
Responses from CritiTech Particle Engineering Solutions’ initial spray drying customers have been positive. For example, upon completion of their project, a multi-billion-dollar spray drying client remarked, “Thank you for the wonderful work you have done on this project. Your skills and work ethic are exemplary and unique. We look forward to continuing to work with your company.”
CritiTech Particle Engineering Solutions will expand its CDMO business and add new capabilities and staff as customer demand grows.
About CritiTech Particle Engineering Solutions
CritiTech Particle Engineering Solutions (CT PES) is an established, growing, pharmaceutical Contract Development Manufacturing Organization (CDMO) with extensive experience and expertise in particle engineering, material characterization, analytical testing, early stage drug development, pre-clinical and clinical manufacturing. The company utilizes Spray Drying and Supercritical Precipitation to help its customers develop their drugs. CT PES uses proprietary Supercritical Precipitation Technology and Spray Drying to help its customers improve and optimize the bioavailability of poorly soluble drugs. It also uses these technologies to engineer a wide range of pharmaceutical drugs to improve their efficacy, pharmacokinetics, dosing, delivery and toxicity. CT PES’ clients include three “Top 15” pharma companies.
For more information about CritiTech, please visit www.crititech.com.